4.7 Article

Structural Basis of Inhibition of DCLK1 by Ruxolitinib

期刊

出版社

MDPI
DOI: 10.3390/ijms22168488

关键词

doublecortin-like kinase 1; DCLK1; kinase inhibitor; anticancer; structure-based drug discovery; ATP-competitive inhibitor

资金

  1. National Research Foundation of Korea (NRF) [NRF-2020R1C1C1009512, WISET-2020-437]
  2. National Cancer Center grant of Korea [NCC-1910020, NCC-1910032, NCC-2110510]

向作者/读者索取更多资源

By repurposing a Janus kinase 1 inhibitor, ruxolitinib, as a DCLK1 inhibitor, researchers were able to show micromolar binding affinity and inhibitory activity. The crystal structure of ruxolitinib-complexed DCLK1 provides insight into the interaction mode and could potentially guide the discovery of selective DCLK1 inhibitors.
Given the functional attributes of Doublecortin-like kinase 1 (DCLK1) in tumor growth, invasion, metastasis, cell motility, and tumor stemness, it is emerging as a therapeutic target in gastrointestinal cancers. Although a series of specific or nonspecific ATP-competitive inhibitors were identified against DCLK1, different types of scaffolds that can be utilized for the development of highly selective inhibitors or structural understanding of binding specificities of the compounds remain limited. Here, we present our work to repurpose a Janus kinase 1 inhibitor, ruxolitinib as a DCLK1 inhibitor, showing micromolar binding affinity and inhibitory activity. Furthermore, to gain an insight into its interaction mode with DCLK1, a crystal structure of the ruxolitinib-complexed DCLK1 has been determined and analyzed. Ruxolitinib as a nonspecific DCLK1 inhibitor characterized in this work is anticipated to provide a starting point for the structure-guided discovery of selective DCLK1 inhibitors.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据